Dietary pretreatment with green tea polyphenol, (−)-epigallocatechin-3-gallate reduces the bioavailability and hepatotoxicity of subsequent oral bolus doses of (−)-epigallocatechin-3-gallate. (February 2015)

• Record Type: Journal Article
• Authors: James, Karma D.; Forester, Sarah C.; Lambert, Joshua D.
• Is Part Of: Food and chemical toxicology. Volume 76(2015)
• Page Start: 103
• Page End: 108
• Publication Date: 2015-02
• Subjects: ALT alanine aminotransferase -- AUC0→6h exposure over 6 h -- Cmax maximum concentration -- EGCG (−)-epigallocatechin-3-gallate -- GAPDH glyceraldehyde-3-phosphate dehydrogenase -- GPX glutathione peroxidase -- GSR glutatione reductase -- GST glutathione-S-transferase -- γH2AX phosphorylated histone 2AX -- SOD superoxide dismutase -- qPCR quantitative reverse transcriptase polymerase chain reaction; Green tea -- Camellia sinensis -- (−)-Epigallocatechin-3-gallate -- Hepatotoxicity -- Bioavailability; Toxicology -- Periodicals; Food poisoning -- Periodicals; Food Poisoning -- Periodicals; Toxicology -- Periodicals; Toxicologie -- Périodiques; Intoxications alimentaires -- Périodiques; Food poisoning; Toxicology; Periodicals; Electronic journals; 615.9
• DOI: 10.1016/j.fct.2014.12.009
• Languages: English
• ISSNs: 0278-6915

Abstract

Highlights: Pretreatment with dietary (−)-epigallocatechin-3-gallate (EGCG) mitigated the hepatotoxicity of oral bolus EGCG in mice. Pretreatment with dietary EGCG prevented a reduction in hepatic antioxidant gene expression caused by oral bolus EGCG in mice. Dietary pretreatment with EGCG reduced the plasma and hepatic bioavailability of subsequent oral bolus EGCG in mice. Abstract: Human case-studies have reported an association between green tea-based dietary supplements and hepatotoxicity. Studies have demonstrated the hepatotoxicity of high-dose oral bolus dosing with the tea polyphenol (−)-epigallocatechin-3-gallate (EGCG) in mice and dogs. We examined the effect of pretreatment with dietary EGCG on the hepatotoxicity and bioavailability of acute oral bolus dosing with EGCG in CF-1 mice. EGCG (750 mg/kg, i.g., once daily for 3 days) increased plasma alanine aminotransferase by 80-fold, decreased both reduced (by 59%) and total (by 33%) hepatic glutathione, and increased hepatic levels of phosphorylated histone 2AX. Pretreatment with dietary EGCG (3.2 mg/g diet) for 2 weeks mitigated hepatotoxicity. Acute oral EGCG also decreased mRNA expression of glutathione reductase. Dietary pretreatment prevented these decreased and increased glutathione peroxidase (Gpx)2, Gpx3, Gpx5, and Gpx7 expression. We found that dietary EGCG reduced the plasma (57% reduction) and hepatic (71% reduction) EGCG exposure following oral bolus dosing compared to mice that were not pre-treated. Overall, it appears that EGCG can modulate its own bioavailability and that dietary treatment may reduce the toxic potential of acute high oral bolus doses of EGCG. These data may partly explain the observed variation in hepatotoxic response to green tea-containing dietary supplements.